- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06055465
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer
February 28, 2024 updated by: Molly SC Li, Chinese University of Hong Kong
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer: an Open-label, Multicenter, Single Arm Phase 2 Study
The combination of neoadjuvant immunotherapy plus chemotherapy has recently been shown to improve survival outcome compared to chemotherapy alone and was recently approved for resectable non-small cell lung cancer (NSCLC).
Despite so, recurrence risk of NSCLC after surgical resection remains high.
Sacituzumab govitecan, a novel antibody drug conjugate, was demonstrated to be clinically active in metastatic NSCLC.
This study aims to study the clinical efficacy of sacituzumab govitecan plus immunotherapy in resectable NSCLC.
This is a open-label, single arm, multicentre, phase II study.
Patients with EGFR/ALK negative, stage II-III (AJCC 8th edition), resectable NSCLC are eligible and will receive 4 cycles of neoadjuvant pembrolizumab plus sacituzumab govitecan, followed by surgical resection of tumour, and then 13 cycles of maintenance pembrolizumab.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
37
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Molly SC LI, MBBS, MRCP
- Phone Number: 3505 2166
- Email: molly@clo.cuhk.edu.hk
Study Contact Backup
- Name: Sherlaine YAU, RN
- Phone Number: 3505 1202
- Email: sherlaineyau@clo.cuhk.edu.hk
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- Department of Clinical Oncology, Prince of Wales Hospital
-
Contact:
- Molly SC LI, MBBS, MRCP
- Phone Number: 3505 2166
- Email: molly@clo.cuhk.edu.hk
-
Contact:
- Sherlaine YAU, RN
- Phone Number: 3505 1202
- Email: sherlaineyau@clo.cuhk.edu.hk
-
Hong Kong, Hong Kong
- Not yet recruiting
- Department of Clinical Oncology, Queen Elizabeth Hospital
-
Contact:
- James CH CHOW, MSc, MBChB
- Phone Number: 3506 2413
- Email: cch932@ha.org.hk
-
Hong Kong, Hong Kong
- Not yet recruiting
- Department of Clinical Oncology, Tuen Mun Hospital
-
Contact:
- Shi Feng NYAW, MSc, MBChB
- Phone Number: 2468 5087
- Email: sfnyaw@ha.org.hk
-
Hong Kong, Hong Kong
- Not yet recruiting
- Department of Oncology, Princess Margaret Hospital
-
Contact:
- Fiona M LIM, MBChB
- Phone Number: 2990 2781
- Email: imy084@ha.org.hk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Female or male patients, 18 years of age or older, able to understand and give written informed consent
- Pathologically proven NSCLC
- Tumour tested negative for EGFR and ALK
- Measurable disease by CT as per RECIST Version 1.1 criteria by investigator
- Tumour tissue is available for translational research (preferably histology, cytology allowed)
AJCC 8th edition Stage II-III based on the following diagnostic workup and tumour is considered potentially resectable
- Distant metastasis staging by PET/CT whole body or CT thorax and upper abdomen with contrast
- Patients with stage IIIB (N2) that is considered potentially resectable by cardiothoracic surgeon may be enrolled
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
- Adequate haematological values without transfusional or growth factor support within 2 weeks of study drug initiation: haemoglobin ≥ 9.0g/dL, absolute neutrophil count ≥ 1.5 x 10^9/L, platelet count ≥ 100 x 10^9/L
- Adequate hepatic function: bilirubin ≤ 1.5 x ULN, AST/ALT ≤ 2.5 x ULN
- Adequate renal function: calculated creatinine clearance ≥ 30 ml/min, according to the formula of Cockcroft-Gault equation
- Male patients and female patients of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception as described in Appendix V.
- Patients with HBV (HBsAg +ve) must be on antiviral therapy and have a well-controlled HBV infection as determined by investigator. Patients who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease. Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention.
- Patients with known HCV infection (positive hepatitis C antibody) (testing is not mandatory for trial enrolment) must have been treated with antiviral therapy and have undetectable HCV viral load.
- Willing and able to comply with the requirements and restrictions in this protocol.
Exclusion Criteria:
- Presence of any distant metastasis
- Previous or concomitant malignancy within 5 years prior registration with the exception of adequately treated localized non-melanoma skin cancer or cervical carcinoma in situ. Prior anti-cancer treatment can be accepted except for drugs listed in exclusion criteria (3) to (8)
- Received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to study treatment Day 1
- Mixed SCLC and NSCLC histology
- Any previous treatment with a PD-1 or PD-L1 or CTLA4 inhibitor, or another agent directed to stimulatory or coinhibitory T-cell receptor (OX40, CD137, etc)
- Any previous treatment with sacituzumab govitecan, topoisomerase inhibitor, or TROP-2 targeted therapy.
- Previous radiotherapy to the chest including radiation to mediastinal tumours (e.g. germ cell tumours and thymic tumours)
- Positive pregnancy test by urine or serum (Appendix V) or women who are breastfeeding
- Known hypersensitivity to pembrolizumab or Sacituzumab govitecan, or their metabolites or formulation excipient
- Requirement for ongoing therapy with or prior use of any prohibited medications listed in Appendix IV
- Absolute contraindications for the use of corticosteroids as premedication
- Concurrent treatment with other experimental drugs or other anticancer therapy, treatment in a clinical trial within 30 days prior to registration
- Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment
- Current or prior use of immunosuppressive medication within 28 days before the first dose of pembrolizumab or sacituzumab govitecan, with the exceptions of intranasal and inhaled corticosteroid or systemic corticosteroids at physiological doses (i.e. which must not exceed 10mg/day of prednisone or an equivalent corticosteroid) and the premedication for chemotherapy.
- Severe or uncontrolled cardiac disease, congestive heart failure NYHA class III or IV, unstable angina pectoris, history of myocardial infarction during the last 3 months, serious arrhythmias requiring medication (with the exception of atrial fibrillation or paroxysmal supraventricular tachycardia under medical control); history of QTc interval prolongation
- Clinically severe pulmonary compromise resulting from intercurrent pulmonary illness including, but not limited to, any underlying pulmonary disorder (ie pulmonary embolism within 3 months of enrolment, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc.); history of (non-infectious) pneumonitis that required steroids or recurrent pneumonitis; any autoimmune/connective tissue/inflammatory disorders with pulmonary involvement, or prior pneumonectomy.
- Active autoimmune disease requiring systemic treatment within the past 2 years or a documented history of clinically severe autoimmune disease or a syndrome that requires systemic steroids or immunosuppressive agents with the exception of resolved childhood asthma/atopy, hypothyroidism or adrenal insufficiency on hormone replacement, diabetes mellitus stable on insulin replacement
- Active HBV or HCV infection
- Known history of Human Immunodeficiency Virus (HIV).
- History of primary immunodeficiency
- History of allogeneic organ transplant
- Receipt of live attenuated vaccination any time during trial therapy and within 30 days of receiving the last dose of trial therapy. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed. COVID-vaccination is allowed.
- Any concomitant drugs contraindicated for use with pembrolizumab or sacituzumab govitecan including systemic corticosteroid, methotrexate, azathioprine, TNF-alpha blockers.
- Any other serious underlying medical, psychiatric, psychological, familial condition that in the judgement of the investigator, that may interfere with planned staging, treatment and follow up, affect patient compliance, or place the patient at high risk from treatment-related complications.
- Patients who refuse surgical treatment of the lung cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sacituzumab Govitecan and Pembrolizumab
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pathological complete response (pCR) rate in the intention-to-treat population
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: 2 years
|
2 years
|
|
Resection rate after neoadjuvant SG and pembrolizumab combination: proportion of patients who undergo surgery with curative intent
Time Frame: 2 years
|
2 years
|
|
pCR rates in patients who undergo surgery
Time Frame: 2 years
|
2 years
|
|
Major pathological response (MPR) rate in the ITT population and in patients who undergo surgery: MPR is defined as less than 10% viable tumor cells in resected primary tumour specimen
Time Frame: 2 years
|
2 years
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 while on neoadjuvant SG and pembrolizumab combination
Time Frame: 2 years
|
2 years
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 while on adjuvant pembrolizumab
Time Frame: 2 years
|
2 years
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 first 30 days after surgery
Time Frame: 2 years
|
2 years
|
|
Objective response rate (ORR): rate of partial and complete response on CT scans according to RECIST criteria ver 1.1
Time Frame: 2 years
|
2 years
|
|
12 month and 24 month event-free survival (EFS) rate
Time Frame: 2 years
|
2 years
|
|
Patient reported quality of life (QOL), as measured by EQ-5D-3L during study treatment.
Time Frame: 2 years
|
For the descriptive system of EQ-5D-3L, three levels of problems are described in each dimension.
For the Visual Analogue Scale (VAS), the overall health assessment of the respondent is captured, ranging from 0 (worst health imaginable) to 100 (best health imaginable)
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 28, 2024
Primary Completion (Estimated)
December 30, 2028
Study Completion (Estimated)
December 30, 2029
Study Registration Dates
First Submitted
August 24, 2023
First Submitted That Met QC Criteria
September 20, 2023
First Posted (Actual)
September 26, 2023
Study Record Updates
Last Update Posted (Estimated)
February 29, 2024
Last Update Submitted That Met QC Criteria
February 28, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Immunoconjugates
- Pembrolizumab
- Sacituzumab govitecan
Other Study ID Numbers
- LUN109
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on Sacituzumab Govitecan
-
Icahn School of Medicine at Mount SinaiNot yet recruitingOvarian Cancer | Malignant Neoplasm of UterusUnited States
-
Gilead SciencesApproved for marketingMetastatic Triple-Negative Breast Carcinoma
-
Fudan UniversityRecruiting
-
The University of Texas Health Science Center at...Recruiting
-
M.D. Anderson Cancer CenterGilead SciencesRecruitingSalivary Gland Cancers | GlandUnited States
-
SOLTI Breast Cancer Research GroupNot yet recruitingBreast Cancer Stage IVSpain
-
The University of Texas Health Science Center at...Gilead SciencesActive, not recruiting
-
Georgetown UniversityGilead SciencesRecruitingThymic Carcinoma | ThymomaUnited States
-
University Hospital HeidelbergNot yet recruitingMetastatic Colorectal CancerGermany
-
National Cancer Institute (NCI)RecruitingAdvanced Solid Tumors | SCLC | HRD CancerUnited States